Oncology Medical News about neuroendocrine carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma
The Journal of Thoracic and Cardiovascular Surgery, 04/03/09

Iyoda A et al. - In a study to explore the clinical features of recurrent tumors of large-cell neuroendocrine carcinoma and examine the role of adjuvant chemotherapy and management of recurrence in pts with large-cell neuroendocrine carcinoma, it was found that pts with large-cell neuroendocrine carcinoma had frequent recurrence following resection of the primary tumor, and those without recurrence often developed metachronous second primary cancers. Platinum-based adjuvant chemotherapy after surgery may be useful for preventing recurrence in pts with large-cell neuroendocrine carcinoma.

Methods

Clinical data from 79 pts was retrospectively analyzed.
Prognosis of pts with platinum-based adjuvant chemotherapy, recurrence patterns, pt response to chemotherapy or radiation therapy, and prognosis in pts who experienced relapse were evaluated.

Results

36 of 72 pts had confirmed recurrent tumors on follow-up exams.
Of those with recurrent tumors, 33 pts (91.7%) had their first recurrent tumors within 3 yrs.
Pts who underwent platinum-based adjuvant chemotherapy had a significantly lower rate of tumor recurrence and higher rate of disease-free survival than those who had non–platinum-based adjuvant chemotherapy or no adjuvant chemotherapy.
Multivariate analyses revealed that platinum-based adjuvant chemotherapy, pathologic stage, and presence of second cancer are independent prognostic factors.
3 pts with limited resection of the primary tumor had poor prognosis with recurrence.
Postoperatively, 11 of 36 pts without recurrence (30.6%) had metachronous second primary cancers, of which 4 pts had >1 site.

<< Previous
188Re-HEDP combined with capecitabine in hormone-refractory...

Next >>
Pilocytic astrocytoma of the optic pathway: a tumour deriving...